Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides ...

Retrospective study finds link between blockbuster drugs and longer survival ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

Results showed that use of GLP-1 receptor agonists did not increase short-term medical or surgical complications among ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve ...

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.